Pfizer, Genmab get full FDA approval for cervical-cancer drug
By Ben Glickman
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
The companies' drug Tivdak had previously been granted accelerated approval by the U.S. Food and Drug Administration, which allows quicker approval for drugs addressing a serious unmet need. The FDA's full approval covers Tivdak in the treatment of recurrent or metastatic cervical cancer.
Danish biotechnology company Genmab and Pfizer-owned Seagen codeveloped Tivdak under a cost- and profit-sharing agreement.
Tivdak has had accelerated approval from the FDA for cervical-cancer treatment since 2021.
Genmab (GMAB) and Pfizer (PFE) said Monday that the antibody-drug conjugate had been approved to treat patients who have disease progression on or after chemotherapy, meaning it is a second-line treatment.
The approval was based on results from a Phase 3 trial of Tivdak, which met its primary endpoint of overall survival as well as its secondary endpoints, the companies said.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-29-24 1858ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?